New approaches might lower drug prices

09/26/2013 | Reuters

Targeted clinical trials, wherein compounds are tested on patients with specific genetic traits, might lower development costs and subsequent prices for promising immunotherapies. Drugmakers are also experimenting with combinations of existing treatments that might cost less than single compounds. The FDA has become more flexible, speeding the approval process for drugs designated as breakthroughs and giving others priority review.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN